Objective: Lung cancer patients often experience profound physical and psychosocial changes as a result of disease progression or treatment side effects. Fatigue, pain, dyspnea, depression, and sleep disturbances appear to be the most common symptoms in such patients. The objective of the present study was to examine the prevalence of symptoms in lung cancer patients in order to identify subgroups (clusters) of patients, grouped according to the magnitude of the symptoms, as well as to compare the quality of life among the identified subgroups.
Methods: A cross-sectional study involving agglomerative hierarchical clustering. A total of 50 lung cancer patients were evaluated in terms of their demographic characteristics and their scores on three quality of life questionnaires, namely the 30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Lung, and the Medical Outcomes Study 36-item Short-form Survey. The cluster analysis took into account the magnitude of the most prevalent symptoms as assessed by the EORTC QLQ-C30 symptom scale scores; those symptoms were fatigue, pain, dyspnea, and insomnia.
Results: Three clusters (subgroups)_of patients were identified on the basis of the magnitude of the four most prevalent symptoms. The three subgroups of patients were as follows: patients with mild symptoms (n = 30; 60%); patients with moderate symptoms (n = 14; 28%); and patients with severe symptoms (n = 6; 12%). The subgroup of patients with severe symptoms had the worst quality of life, as assessed by the total scores and by the integrated domains of all three instruments.
Conclusions: This study highlights the importance of symptom cluster assessment as an important tool to assess the quality of life of patients with chronic diseases, such as lung cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075800 | PMC |
http://dx.doi.org/10.1590/s1806-37132013000100004 | DOI Listing |
Psychiatry Clin Psychopharmacol
December 2024
Department of Operating Room, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, China.
Background: Interventional therapy, currently, has become a major method for the clinical treatment of liver cancer patients. However, interventional therapy can also lead to various toxic side effects, and combined with the impact of the disease itself, liver cancer patients often experience more severe emotional distress. Improving individuals' levels of psychological distress tolerance may reduce sensitivity to negative life events and experiences.
View Article and Find Full Text PDFPsychiatry Clin Psychopharmacol
December 2024
Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.
Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).
Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO.
Vaccines (Basel)
December 2024
GSK México, Torre Mitikah Piso 19 y 20, Circuito Interior Avenida Río Churubusco 601, Col. Xoco. Alc. Benito Juárez, Mexico City 03330, Mexico.
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
GSK, Ho Chi Minh City 70000, Vietnam.
The burden of herpes zoster (HZ) is recognized worldwide; however, there is seemingly limited information on incidence and vaccination practices in Southeast Asia (SEA). A scientific workshop was held by the Zoster Experts' Network to exchange and consolidate insights on the burden of HZ and the patient pathway in SEA. The workshop included practicing clinical experts and public health specialists/epidemiologists from Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida 400, 4200-072 Porto, Portugal.
The World Health Organization estimates that currently available vaccines prevent 2 to 3 million deaths worldwide each year. Preventing infectious diseases is an important public health priority to ensure healthy ageing and improve quality of life. This study's aim is to identify the best strategies to increase vaccination coverage in the elderly.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!